Related Experiment Video
Updated: Feb 13, 2026

Generation and Isolation of Cell Cycle-arrested Cells with Complex Karyotypes
Published on: April 13, 2018
Knockdown of MRPL42 suppresses glioma cell proliferation by inducing cell cycle arrest and apoptosis
Chunyan Hao1, Hubin Duan2, Hao Li3
1Department of Geriatrics, First Clinical Medical College of Shanxi Medical University, 85 Jie Fang South Road, Taiyuan, 030001, Shanxi Province, People's Republic of China.
Abstract:
Mammalian mitochondrial ribosomal proteins are functionally involved in protein synthesis in mitochondrion. Recently numerous studies have illuminated the role of mitochondrion in cancer development. However, the precise function of mitochondrial ribosomal protein L42 (MRPL42) remains unclear. Here in the present study, we identified MRPL42 as a novel oncogene in glioma. By analyzing the Cancer Genome Atlas (TCGA) database, we first found that MRPL42 was significantly up-regulated in glioma tissues compared with normal tissues. Functionally, we silenced MRPL42 in glioma cells and revealed that MRPL42 knockdown largely blunted the proliferation of U251 and A172 cells. Mechanistically, our results suggested that MRPL42 silencing resulted in increased distribution of cell cycle in G1 and G2/M phases, while the S-phase decreased. In addition, the apoptosis and caspase3/7 activity were both activated after MRPL42 knockdown. Taken together, MRPL42 is a novel oncogene in glioma and might help us develop promising targetted therapies for glioma patients.
Insights
Mitochondrial ribosomal protein L42 (MRPL42) is a newly identified oncogene in glioma. Its knockdown inhibits glioma cell proliferation, suggesting MRPL42 as a potential therapeutic target for brain tumors.
Area of Science:
- Molecular Biology
- Oncology
- Mitochondrial Biology
Background:
- Mitochondrial ribosomal proteins are crucial for mitochondrial protein synthesis.
- The role of mitochondria in cancer development is increasingly recognized.
- The specific function of mitochondrial ribosomal protein L42 (MRPL42) in cancer, particularly glioma, is not well understood.
Purpose of the Study:
- To investigate the role of MRPL42 in glioma.
- To determine if MRPL42 functions as an oncogene in glioma.
- To explore the potential of MRPL42 as a therapeutic target for glioma.
Main Methods:
- Analysis of The Cancer Genome Atlas (TCGA) database for MRPL42 expression in glioma tissues.
- MRPL42 gene silencing in human glioma cell lines (U251 and A172).
- Cell proliferation assays, cell cycle analysis, and apoptosis assays (including caspase 3/7 activity).
Main Results:
- MRPL42 expression is significantly upregulated in glioma tissues compared to normal tissues.
- MRPL42 knockdown markedly inhibits the proliferation of U251 and A172 glioma cells.
- Silencing MRPL42 leads to cell cycle arrest in G1 and G2/M phases, decreased S-phase, and induced apoptosis with activated caspase 3/7.
Conclusions:
- MRPL42 acts as a novel oncogene in glioma.
- MRPL42 promotes glioma cell proliferation and inhibits apoptosis.
- MRPL42 represents a promising therapeutic target for developing targeted therapies for glioma patients.
Related Concept Videos
What is the Cell Cycle?
What is the Cell Cycle?
Cells Coordinate Growth and Proliferation
The Cell Cycle Control System
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and...
The Cell Cycle Control System
Mitogens and the Cell Cycle

